» Articles » PMID: 38003983

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Nov 25
PMID 38003983
Authors
Affiliations
Soon will be listed here.
Abstract

: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn's disease (CD) and ulcerative colitis (UC). One of the extraintestinal manifestations of IBD is nonalcoholic fatty liver disease (NAFLD). IBD and NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination is the most commonly used imaging method for the diagnosis of NAFLD. This cross-sectional observational retrospective study aimed to evaluate the US prevalence of NAFLD in IBD patients and their clinical features. : A total of 143 patients with IBD underwent hepatic US and were divided into two different groups according to the presence or absence of NAFLD. Subsequently, new exclusion criteria for dysmetabolic comorbidities (defined as plus) were applied. : The US prevalence of NAFLD was 23% (21% in CD and 24% in UC, respectively). Most IBD-NAFLD patients were male and older and showed significantly higher values for body mass index, waist circumference, disease duration, and age at onset than those without NAFLD. IBD-NAFLD patients showed a significantly higher percentage of stenosing phenotype and left-side colitis. Regarding metabolic features, IBD-NAFLD patients showed a significantly higher percentage of hypertension and IBD plus dysmetabolic criteria. Also, higher values of alanine aminotransferase and triglycerides and lower levels of high-density lipoproteins are reported in these patients. : We suggest performing liver US screening in subjects affected by IBD to detect NAFLD earlier. Also, patients with NAFLD present several metabolic comorbidities that would fall within the new definition of metabolic-associated fatty liver disease. Finally, we encourage larger longitudinal studies, including healthy controls, to provide further confirmation of our preliminary data.

Citing Articles

Construction of a Compound Model to Enhance the Accuracy of Hepatic Fat Fraction Estimation with Quantitative Ultrasound.

Boglarka Z, Zsombor Z, Ronaszeki A, Egresi A, Stollmayer R, Himsel M Diagnostics (Basel). 2025; 15(2).

PMID: 39857087 PMC: 11763894. DOI: 10.3390/diagnostics15020203.


Effect of powder combined with conventional therapy on mild to moderate fatty liver.

Le X, Zhang Y, Yang M, Li J, Wang H, Wu J World J Gastroenterol. 2024; 30(45):4791-4800.

PMID: 39649546 PMC: 11606375. DOI: 10.3748/wjg.v30.i45.4791.


The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial.

Papaefthymiou A, Sarrou S, Pateras K, Vachliotis I, Agrotis G, Sgantzou I Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598344 PMC: 11597268. DOI: 10.3390/ph17111432.


Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study.

Abenavoli L, Spagnuolo R, Scarlata G, Gambardella M, Boccuto L, Mendez-Sanchez N Life (Basel). 2024; 14(10).

PMID: 39459526 PMC: 11509059. DOI: 10.3390/life14101226.


Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients.

Argenziano M, Kim M, Montori M, Di Bucchianico A, Balducci D, Ahn S Hepatol Int. 2024; 18(Suppl 2):922-940.

PMID: 39012579 DOI: 10.1007/s12072-024-10692-4.


References
1.
Abenavoli L, Beaugrand M . Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol. 2012; 11(2):172-8. View

2.
Hoffmann P, Jung V, Behnisch R, Gauss A . Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis. World J Gastroenterol. 2020; 26(46):7367-7381. PMC: 7739163. DOI: 10.3748/wjg.v26.i46.7367. View

3.
Cho C, You M, Oh C, Lee C, Moon S . Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. Gut Liver. 2021; 16(2):157-170. PMC: 8924800. DOI: 10.5009/gnl210118. View

4.
Zarghamravanbakhsh P, Frenkel M, Poretsky L . Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open. 2021; 12:100149. PMC: 8626571. DOI: 10.1016/j.metop.2021.100149. View

5.
Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos S . Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis. 2021; 16(5):852-862. DOI: 10.1093/ecco-jcc/jjab212. View